

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number  
WO 01/035942 A3

(51) International Patent Classification<sup>7</sup>: A61K 31/485,  
A61P 25/04

(21) International Application Number: PCT/GB00/04372

(22) International Filing Date:  
17 November 2000 (17.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9927359.1 19 November 1999 (19.11.1999) GB  
60/176,208 14 January 2000 (14.01.2000) US

(71) Applicant (for all designated States except US):  
RECKITT BENCKISER HEALTHCARE (UK)  
LIMITED [GB/GB]; 103-105 Bath Road, Slough, Berk-  
shire SL1 3UH (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHAPLEO,  
Christopher, Bourne [GB/GB]; Linden House, The  
Falconers, Redbourne, Gainsborough DN21 4AS (GB).  
MCCORMACK, Keith [GB/GB]; Church House, Church  
Square, Leighton Buzzard, Bedfordshire LU7 7AE (GB).  
VAREY, Nicolas, Calvert [GB/GB]; "Caduceus", Main  
Street, Knedlington, Goole, North Humberside DN14 7EU  
(GB).

(74) Agent: DICKSON, Elizabeth, Anne; Reckitt Benckiser  
plc, Group Patents Dept., Dansom Lane, Hull HU8 7DS  
(GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
13 June 2002

(48) Date of publication of this corrected version:  
28 November 2002.

(15) Information about Correction:  
see PCT Gazette No. 48/2002 of 28 November 2002, Sec-  
tion II

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: ANALGESIC COMPOSITIONS CONTAINING BUPRENORPHINE

(57) Abstract: An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmeferene such that the ratio by weight of buprenorphine to naltrexone or nalmeferene is in the range of from 12.5:1 to 22.5:1, whereby the analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmeferene.

WO 01/035942 A3

## ANALGESIC COMPOSITIONS CONTAINING BUPRENORPHINE

The present invention relates to analgesic compositions, containing buprenorphine and, in particular, to compositions which contain buprenorphine at a sub-clinical analgesic dose level in combination with naloxone, naltrexone or nalmeffene.

Buprenorphine (International Non-proprietary Name for N-cyclopropylmethyl-7 $\alpha$ -[1-(S)-hydroxy-1,2,2-trimethylpropyl]6,14-endoethano-6,7,8,14-tetrahydro-nororipavine) has been shown in clinical trials to be a potent opiate partial agonist analgesic lacking the psychotomimetic effects found with other opiate analgesics. Buprenorphine effectively relieves moderate to severe pain in doses of 0.1 mg or more administered either parenterally or sublingually. The optimum therapeutic range for single doses is 0.3 mg - 0.6 mg by injection and 0.2 mg-0.8 mg for sublingual tablets.

In animal tests and in man buprenorphine has been shown to have both agonist (morphine-like) and antagonist properties. However from direct dependence studies in animals and in man it has been concluded that buprenorphine does not produce significant physical dependence, as indicated by animal self administration studies and by the measurement of euphorigenic effects in human post addicts. However, buprenorphine suffers from side effects typical of opiate agonists such as nausea and vomiting, constipation and respiratory depression in some patients, although there is a ceiling to its effects on respiratory depression as a direct consequence of its partial agonist properties.

Naloxone (International Non-proprietary Name for 1-N-allyl-14-hydroxynorhydromorphinone) is a narcotic antagonist which has been incorporated into oral and sublingual preparations of various opioids in order to protect the preparations from parenteral abuse, whilst maintaining the analgesic effect of the opioid.

GB-A-2150832 describes analgesic compositions in sublingual or parenteral dosage form comprising an active

2 -

dose of buprenorphine and an amount of naloxone sufficient to prove aversive to a narcotic addict by parenteral administration but insufficient to compromise the analgesic action of the buprenorphine. Preferably  
5 the parenteral dosage form contains naloxone and buprenorphine within the weight ratio of 1:3 to 1:1 and the sublingual form within the ratio 1:2 to 2:1.

Naltrexone (International Non-proprietary Name for 1-N-cyclopropylmethyl-14-hydroxynordihydro-morphinone) is  
10 a pure opiate antagonist which, when administered orally (50 mg/day) as a maintenance drug for opiate addicts, blocks the effects of self-administered opiates and this contributes to the extinction of drug craving.

Nalmefene (International Non-Proprietary Name for  
15 (5 $\alpha$ )-17-(cyclopropylmethyl)-4,5-epoxy-6-methylene-morphinan-3,14-diol) is a structural analogue of naltrexone with opiate antagonist activity.

GB-A-2167633 describes an analgesic composition in parenteral or sublingual unit dosage form comprising an  
20 active dose of buprenorphine and an amount of naltrexone sufficient to prove aversive to a narcotic addict by parenteral administration but insufficient to compromise the analgesic action of the buprenorphine wherein the dose of buprenorphine in the parenteral form is from  
25 about 0.3mg to about 0.6mg and in the sublingual form from about 0.1mg to about 0.4mg and the weights of buprenorphine to naltrexone for the parenteral form are within the ratio of 12:1 to 3:1 and for the sublingual form are within the ratio 4:1 to 1:1.

30 We have now surprisingly found that sub-clinical dosage levels of buprenorphine are potentiated and enhanced by low doses of naloxone or naltrexone or nalmefene. The interaction between the drugs is a synergistic interaction and more than the additive  
35 effects of the separate drug entities.

Accordingly, the present invention provides in its broadest aspect an analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of

3-

buprenorphine which is less than the clinical dose required to achieve pain relief and

- (i) an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or
- (ii) an amount of naltrexone or nalmeferine such that the ratio by weight of buprenorphine to naltrexone or nalmeferine is in the range of from 12.5:1 to 22.5:1

whereby the analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmeferine.

In a first aspect the present invention provides an analgesic composition in parenteral or sublingual unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising from 15µg to 200µg of buprenorphine per unit dose and

- (i) an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or
- (ii) an amount of naltrexone or nalmeferine such that the ratio by weight of buprenorphine to naltrexone or nalmeferine is in the range of from 12µ5:1 to 22µ5:1.

It is to be understood that the terms buprenorphine, naloxone, naltrexone and nalmeferine as used herein are meant to cover not only the bases but their pharmaceutically acceptable salts. Particularly preferred salts are the hydrochlorides.

It is preferable to formulate the compositions in unit dosage forms i.e. physically discrete units containing the appropriate amounts of buprenorphine and naloxone, naltrexone or nalmeferine, together with pharmaceutically acceptable diluents and/or carriers.

Such unit dosage forms for parenteral administration are suitably in the form of ampoules and for delivery via the mucosa may, for example, be in the form of tablets for sublingual administration.

4-

The term parenteral is intended to encompass administration of the compositions by any way other than through the alimentary tract.

The term mucosa is intended to encompass any mucous  
5 membrane and includes oral mucosa, rectal mucosa, vaginal mucosa and nasal mucosa.

Compositions intended for parenteral administration comprise an isotonic solution of buprenorphine and naloxone, naltrexone or nalmefene in sterile water.  
10 Conveniently the solution is made isotonic by use of dextrose and sterilised by autoclaving or by filtration through a membrane filter. The compositions may be administered intramuscularly, intradermally, intraperitoneally, intravenously, intraarterially,  
15 subcutaneously or by the epidural route. The compositions may also be administered transdermally.

Compositions in the form of sublingual tablets contain soluble excipients such as lactose, mannitol, dextrose, sucrose or mixtures thereof. They will also  
20 contain granulating and disintegrating agents such as starch, binding agents such as povidone or hydroxypropylmethyl cellulose and lubricating agents such as magnesium stearate.

The compositions for parenteral administration, or  
25 for delivery via the mucosa, such as by sublingual administration, as detailed above, may be prepared by manufacturing techniques which are well known to those skilled in the art.

The compositions of the present invention in unit  
30 dosage form preferably contain the naloxone, naltrexone or nalmefene in an amount such that the ratio by weight of buprenorphine to naloxone, naltrexone or nalmefene is in the range of from 15:1 to 20:1.

The compositions of the present invention contain  
35 buprenorphine in an amount which is below that required in a unit dose to obtain pain relief. In the human being, dosages of about 40µg of buprenorphine per kilogram of body weight are required to obtain satisfactory pain relief in the absence of potentiation.

5-

Thus for typical body weights of 50 to 80 kg, the dosage would be from 2000µg to 3200µg, i.e. from 2mg to 3.2mg of buprenorphine per day. This would conveniently be administered as 4 unit doses. The amounts of  
5 buprenorphine which are effective in the present invention are below the amounts which are effective in the absence of the potentiating effects of naloxone, naltrexone or nalmeferene.

In a second aspect the present invention provides a  
10 method for the treatment of pain in a human or animal subject, which method comprises the administration to the human or animal by the parenteral or via the mucosa route of from 1.25µg to 10µg per kilogram of body weight of buprenorphine per day and

- 15 (i) an amount of naloxone such that the ratio by weight of buprenorphine to naloxone administered is in the range of from 12.5:1 to 27.5:1, or  
(ii) an amount of naltrexone or nalmeferene such that  
20 the ratio by weight of buprenorphine to naltrexone or nalmeferene administered is in the range of from 12.5:1 to 22.5:1.

In a third aspect the present invention provides the use  
25 of naloxone, naltrexone or nalmeferene in the manufacture of a medicament for the treatment of pain comprising a sub-clinical amount of buprenorphine, wherein the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1 or the ratio by weight of  
30 buprenorphine to naltrexone or nalmeferene is in the range of from 12.5:1 to 22.5:1.

The ratios for the potentiation of the sub-clinical dosages of buprenorphine by low doses of the opiate antagonists were determined by the University Department  
35 of Anaesthesia, Addenbrookes Hospital, Cambridge according to the paw withdrawal method of Hargreaves, K.M., Dubner, R., Brown, F., Flores, C. and Joris, J.: A New and Sensitive Method for Measuring Thermal Nociception in Cutaneous Hyperalgesia. Pain 32: 77-88,

6-

1988. This method enables the researcher to discern a peripherally mediated response to thermal stimulation caused by drugs in the unrestrained rat.

The results were obtained using a BASILE Plantar Test Device (Ugo Basile, Comerio-Italy). It basically consists of a movable I.R. (infrared) Generator placed below a glass pane upon which the operator places the rat. A perspex enclosure defines the space within which the animal is unrestrained. It is divided into three compartments, which helps the operator to carry out rapid "screening" work: up to three rats can be tested with no appreciable delay in between.

The operator positions the I.R. Generator directly beneath the hind paw of the rat and activates both the I.R. Source and a reaction time counter. When the rat feels pain and withdraws its paw, the I.R. Generator is automatically switched off and the timer stops, determining the withdrawal latency.

The effects of buprenorphine at various dosages, naloxone at various dosages, naltrexone at various dosages and buprenorphine in combination with naloxone or naltrexone at various dosages were determined by testing adult rats in which peripheral mononeuropathy was produced by placing three loosely constrictive ligatures around the common sciatic nerve. The testing was carried out on the eighth day following the operative procedure.

In order to determine a baseline for comparison purposes, rats were subjected to the Hargreaves paw withdrawal test before the subcutaneous injection of the various drugs or drug combinations being tested. The rats were then injected subcutaneously with the particular drug or drug combination being tested and the percentage change in time for the rat to withdraw its paw from the thermal stimulation, in comparison with the baseline, was recorded as a percentage in paw withdrawal latency.

The invention is further described with reference to the following Examples.

7-

## METHODS

### Surgery

Lister Hooded rats (180-200g) were anaesthetised with halothane and the left sciatic nerve was loosely ligated with 3 chromic cat gut sutures to induce a neuropathy.

Rats were left to recover for one week after the procedure before commencing behavioural testing.

### Drug Preparation

The drugs (buprenorphine, naloxone and naltrexone) were prepared freshly in water at a concentration of 1 mg/ml. The stocks were then diluted in saline to obtain the different concentrations used in the study.

Drugs were injected sub-cutaneously in the fold of the neck.

### Testing

After 8 days, thermal nociceptive threshold, as determined by hindpaw withdrawal latency, was measured using a plantar test Ugo Basile, Comerio, Italy). Prior to testing, the rat was placed in the perspex box and allowed 5 minutes to habituate. The heat source was positioned under the plantar surface of one hind paw at random and activated. This initiated a timing circuit which measured the time interval between the application of the light beam and the withdrawal of the hind paw. This value was assigned as the withdrawal latency.

Paw withdrawal latency was determined before injection and at different times after injection. Three measurements were taken per paw.

### EXAMPLE 1

The effects of buprenorphine and buprenorphine/naloxone at weight ratios of 20:1 and 15:1 were determined at various doses of buprenorphine expressed as



8 -

µg/kg of body weight of the drug administered subcutaneously to rats (n=3).

The results of these tests are given in Figure 1. The potentiation of sub-clinical doses of buprenorphine by low dose naloxone can be clearly seen from the graph of Figure 1. Both of the buprenorphine/naloxone combinations showed marked increases in pain withdrawal latencies at both weight ratios where the buprenorphine dose was 1.25µg and 2.5µg, compared to buprenorphine alone which had no significant effect at these dosage levels.

#### EXAMPLE 2

Buprenorphine was administered to rats (n=6) at a dosage level of 2.5µg/kg of body weight of the rats. Buprenorphine was co-administered subcutaneously with either naloxone or naltrexone at various weight ratios ranging from 5:1 to 30:1. In order to provide appropriate baseline points naloxone and naltrexone alone were also administered subcutaneously to rats at the same dosage levels as those used in the combined treatments.

The results are given in Figure 2 from which the potentiation of the sub-clinical doses of buprenorphine by naloxone or naltrexone can be clearly seen.

#### EXAMPLE 3

To investigate the duration of action of several ratios (10:1, 15:1 and 20:1 buprenorphine:naloxone, with a fixed dose of buprenorphine) the effect on PWL was followed over a 26 hour period following subcutaneous injection. The results are given in Figure 3 from which it can be seen that the effect was already maximal after 40 minutes and then decreased sharply over 6 hours. However at 26 hours a residual effect was still visible, although this was not statistically significant. The maximal effect of each ratio (40min) was compatible with the results shown in Figure 2. The effect observed with

9 -

the 10:1 ratio combination was not statistically significant.

#### EXAMPLE 4

5

A parenteral formulation having the following composition:

	mg/ml.
Buprenorphine HCl	0.1
10 Naloxone HCl	0.0067
Anhydrous dextrose	50.0
Hydrochloric acid to pH	4.0
Water for injection to	1.0 ml

15 was prepared by dissolving dextrose, buprenorphine hydrochloride and naloxone hydrochloride in that order with stirring, in about 95% batch volume of Water for Injection. The acidity of the solution was adjusted to pH 4.0 by the addition of 0.1M hydrochloric acid, and the  
20 solution was made up to volume with Water for Injection. The solution was filtered through a 0.22  $\mu$ m membrane filter and transferred to sterilised 1 ml or 2 ml glass ampoules containing 1 ml or 2 ml of the solution. The ampoules were sealed and the product sterilised by  
25 autoclaving.

#### EXAMPLE 5

The formulation of Example 4 was varied by using  
30 0.005 mg/ml of naloxone hydrochloride instead of 0.0067 mg/ml.

#### EXAMPLE 6

35 The formulation of Example 4 was modified with 0.0067 mg/ml of naltrexone hydrochloride substituted for the naloxone hydrochloride of Example 1.

10 -

EXAMPLE 7

The formulation of Example 4 was modified with  
0.005 mg/ml of naltrexone hydrochloride substituted for  
5 the naloxone hydrochloride of Example 1.

EXAMPLE 8

The formulation of Example 4 was modified with  
10 0.0067 mg/ml of nalmeferine hydrochloride substituted for  
the naloxone hydrochloride of Example 4.

EXAMPLE 9

15 The formulation of Example 4 was modified with  
0.005 mg/ml of nalmeferine hydrochloride substituted for  
the naloxone hydrochloride of Example 4.

EXAMPLE 10

20 A sublingual tablet having the following  
composition:

	mg/tablet
25 Buprenorphine HCl	0.1
Naloxone HCl	0.0067
Lactose	31.2433
Mannitol	18.0
Maize starch	9.0
Povidone	1.2
30 Magnesium stearate	<u>0.45</u>
	60.0

was prepared by screening all the materials with the  
exception of the magnesium stearate through a 750  $\mu$ m  
sieve and blending them together. The mixed powders were  
35 then subjected to an aqueous granulation procedure and  
dried at 50°C. The resulting granules were forced  
through a 750  $\mu$ m sieve and blended with magnesium  
stearate (pre-sieved through a 500  $\mu$ m sieve). The tablet

11 -

granules were compressed to yield tablets of 5.56 mm diameter and weight 60 mg.

EXAMPLE 11

5

The formulation of Example 10 was varied by using 0.005 mg/tablet of naloxone hydrochloride and adjusting the weight of lactose.

10

EXAMPLE 12

The formulation of Example 10 was modified with 0.0067 mg/tablet of naltrexone hydrochloride substituted for the naloxone hydrochloride of Example 10.

15

EXAMPLE 13

The formulation of Example 10 was modified with 0.005 mg/tablet of naltrexone hydrochloride substituted for the naloxone hydrochloride of Example 10.

20

EXAMPLE 14

The formulation of Example 10 was modified with 0.0067 mg/tablet of nalmeferne hydrochloride substituted for the naloxone hydrochloride of Example 10.

25

EXAMPLE 15

The formulation of Example 10 was modified with 0.005 mg/tablet of nalmeferne hydrochloride substituted for the naloxone hydrochloride of Example 10.

30

35

12 -

EXAMPLE 16

A suppository having the following composition:

	mg/suppository
5      Buprenorphine HCL	0.1
Naloxone HCL	0.0067
Gelatin	200
Glycerin	700
Deionised water	89.9

10      was prepared by mixing the ingredients together and  
melting them at between 60° and 70°C. The melted mass is  
poured into a disposable mould of plastic material in  
which the suppositories are cast and remain enclosed  
15      until removed by the patient.

EXAMPLE 17

The formulation of Example 16 was varied by using  
20      0.005mg/suppository of naloxone hydrochloride.

EXAMPLE 18

25      The formulation of Example 16 was modified with  
0.0067 mg/suppository of naltrexone hydrochloride  
substituted for the naloxone hydrochloride of Example 16.

EXAMPLE 19

30      The formulation of Example 16 was modified with  
0.005 mg/suppository of naltrexone hydrochloride  
sustituted for the naloxone hydrochloride of Example 16.

EXAMPLE 20

35      The formulation of Example 16 was modified with  
0.0067 mg/suppository of nalmeffene hychloride substituted  
for the naloxone hydrochloride of Example 16.

13 -

EXAMPLE 21

The formulation of Example 16 was modified with  
0.005mg/suppository of nalmeferne hydrochloride  
5 substituted for the naloxone hydrochloride of Example 16.

14 -

## CLAIMS:

1. An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and

- (i) an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or
- (ii) an amount of naltrexone or nalmeferone such that the ratio by weight of buprenorphine to naltrexone or nalmeferone is in the range of from 12.5:1 to 22.5:1

whereby the analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmeferone.

2. An analgesic composition in parenteral or sublingual unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising from 15µg to 200µg of buprenorphine per unit dose and

- (i) an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or
- (ii) an amount of naltrexone or nalmeferone such that the ratio by weight of buprenorphine to naltrexone or nalmeferone is in the range of from 12.5:1 to 22.5:1.

30

15-

3. A composition as claimed in claim 1 or claim 2 wherein the unit dosage form contains an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 15:1 to 20:1.

5

4. A composition as claimed in claim 1 or claim 2 wherein the dosage form contains an amount of naltrexone or nalmeferine such that the ratio by weight of buprenorphine to naltrexone or nalmeferine is in the range of from 15:1 to 20:1.

10

5. A method for the treatment of pain in a human or animal subject, which method comprises the administration to the human or animal by the parenteral or via the mucosa route of from 1.25µg to 10µg per kilogram of body weight of buprenorphine per day and

15

(i) an amount of naloxone such that the ratio by weight of buprenorphine to naloxone administered is in the range of from 12.5:1 to 27.5:1, or

20

(ii) an amount of naltrexone or nalmeferine such that the ratio by weight of buprenorphine to naltrexone or nalmeferine administered is in the range of from 12.5:1 to 22.5:1.

25

6. A method as claimed in claim 5 wherein the amount of buprenorphine administered to the human or animal is from 1.25µg to 5µg per kilogram of body weight.

30

7. A method as claimed in claim 5 or claim 6 wherein the ratio by weight of buprenorphine to naloxone,



16-

naltrexone or nalmeferine administered to the human or animal is in the range of from 15:1 to 20:1.

8. Use of naloxone, naltrexone or nalmeferine in the manufacture of a medicament for the treatment of pain comprising a sub-clinical amount of buprenorphine, wherein the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1 or the ratio by weight of buprenorphine to naltrexone or nalmeferine is in the range of from 12.5:1 to 22.5:1.

9. Use as claimed in claim 8 wherein the ratio by weight of buprenorphine to naloxone, naltrexone or nalmeferine is in the range of from 15:1 to 20:1.

15

10. An analgesic composition according to the invention, substantially as hereinbefore described or exemplified.

20 11. A method for the treatment of pain according to the invention, substantially as hereinbefore described or exemplified.

12. Use as claimed in either one of claims 8 or 9, substantially as hereinbefore described or exemplified.

25

FIGURE 1




FIGURE 2





FIGURE 3



# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/GB 00/04372

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K31/485 A61P25/04

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, BIOSIS, CHEM ABS Data, EMBASE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 02251 A (ALBERT EINSTEIN COLLEGE OF MRDICINE OF YESHIVA UNIVERSITY) 1 February 1996 (1996-02-01) claims 1-3,6,9 page 11, line 33 -page 12, line 1	1,2,5, 10,11
A	GB 2 150 832 A (RECKITT & COLMAN PRODUCTS) 10 July 1985 (1985-07-10) cited in the application claims 1,2	1,2,5, 10,11

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

**\* Special categories of cited documents:**

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

10 July 2001

Date of mailing of the international search report

17/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Peeters, J

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/04372

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>T.EISSENBERG E.A.: "Buprenorphine's physical dependence potential: antagonist-prcipitated withdrawal in humans "</p> <p>JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 276, no. 2, 1996, pages 449-459, XP001010201 page 449 page 455, column 2 -page 458, column 1</p>	<p>1,2,5, 10,11</p>

## INTERNATIONAL SEARCH REPORT

Information on patent family members

Application No

PCT/GB 00/04372

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9602251 A	01-02-1996	US 5512578 A	30-04-1996
		AU 3276995 A	16-02-1996
		AU 4113599 A	23-09-1999
		CA 2195122 A	01-02-1996
		EP 0808165 A	26-11-1997
		JP 10507740 T	28-07-1998
		US 6096756 A	01-08-2000
		US 5580876 A	03-12-1996
		US 5767125 A	16-06-1998
		US RE36547 E	01-02-2000
GB 2150832 A	10-07-1985	AU 569930 B	25-02-1988
		AU 3632984 A	13-06-1985
		CA 1234353 A	22-03-1988
		DE 3477734 D	24-05-1989
		DK 577984 A, B,	07-06-1985
		EP 0144243 A	12-06-1985
		GR 81186 A	08-04-1985
		IE 57876 B	05-05-1993
		JP 1780447 C	13-08-1993
		JP 4069605 B	06-11-1992
		JP 60146824 A	02-08-1985
		NZ 210442 A	29-02-1988
		PT 79615 A, B	01-01-1985
		US 4582835 A	15-04-1986
		ZA 8409463 A	31-07-1985

**THIS PAGE BLANK (USPTO)**



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number  
**WO 01/35942 A3**

- (51) International Patent Classification<sup>7</sup>: **A61K 31/485**,  
A61P 25/04
- (21) International Application Number: **PCT/GB00/04372**
- (22) International Filing Date:  
17 November 2000 (17.11.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
9927359.1 19 November 1999 (19.11.1999) GB  
60/176,208 14 January 2000 (14.01.2000) US
- (71) Applicant (*for all designated States except US*):  
**RECKITT BENCKISER HEALTHCARE (UK)  
LIMITED** [GB/GB]; 103-105 Bath Road, Slough, Berk-  
shire SL1 3UH (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **CHAPLEO,**  
**Christopher, Bourne** [GB/GB]; Linden House, The  
Falconers, Redbourne, Gainsborough DN21 4AS (GB).  
**MCCORMACK, Keith** [GB/GB]; Church House, Church  
Square, Leighton Buzzard, Bedfordshire LU7 7AE (GB).  
**VAREY, Nicolas, Calvert** [GB/GB]; "Caduceus", Main  
Street, Knedlington, Goole, North Humberside DN14 7EU  
(GB).
- (74) Agent: **DICKSON, Elizabeth, Anne**; Reckitt Benckiser  
plc. Group Patents Dept., Dansom Lane, Hull HU8 7DS  
(GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
13 June 2002
- For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: ANALGESIC COMPOSITIONS CONTAINING BUPRENORPHINE

(57) Abstract: An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmefene such that the ratio by weight of buprenorphine to naltrexone or nalmefene is in the range of from 12.5:1 to 22.5:1, whereby the analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmefene.

WO 01/35942 A3

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/04372

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K31/485 A61P25/04

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, BIOSIS, CHEM ABS Data, EMBASE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 02251 A (ALBERT EINSTEIN COLLEGE OF MRDICINE OF YESHIVA UNIVERSITY) 1 February 1996 (1996-02-01) claims 1-3,6,9 page 11, line 33 -page 12, line 1	1,2,5, 10,11
A	GB 2 150 832 A (RECKITT & COLMAN PRODUCTS) 10 July 1985 (1985-07-10) cited in the application claims 1,2	1,2,5, 10,11

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

**\* Special categories of cited documents:**

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

10 July 2001

Date of mailing of the international search report

17/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Peeters, J

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/04372

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>T.EISSENBERG E.A.: "Buprenorphine's physical dependence potential: antagonist-prcipitated withdrawal in humans "</p> <p>JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 276, no. 2, 1996, pages 449-459, XP001010201 page 449 page 455, column 2 -page 458, column 1 -----</p>	<p>1,2,5, 10,11</p>

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/04372

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9602251	A	01-02-1996	US 5512578 A	30-04-1996
			AU 3276995 A	16-02-1996
			AU 4113599 A	23-09-1999
			CA 2195122 A	01-02-1996
			EP 0808165 A	26-11-1997
			JP 10507740 T	28-07-1998
			US 6096756 A	01-08-2000
			US 5580876 A	03-12-1996
			US 5767125 A	16-06-1998
			US RE36547 E	01-02-2000
GB 2150832	A	10-07-1985	AU 569930 B	25-02-1988
			AU 3632984 A	13-06-1985
			CA 1234353 A	22-03-1988
			DE 3477734 D	24-05-1989
			DK 577984 A, B,	07-06-1985
			EP 0144243 A	12-06-1985
			GR 81186 A	08-04-1985
			IE 57876 B	05-05-1993
			JP 1780447 C	13-08-1993
			JP 4069605 B	06-11-1992
			JP 60146824 A	02-08-1985
			NZ 210442 A	29-02-1988
			PT 79615 A, B	01-01-1985
			US 4582835 A	15-04-1986
			ZA 8409463 A	31-07-1985

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number  
**WO 01/35942 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 31/00**

(21) International Application Number: **PCT/GB00/04372**

(22) International Filing Date:  
17 November 2000 (17.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9927359.1 19 November 1999 (19.11.1999) GB  
60/176,208 14 January 2000 (14.01.2000) US

(71) Applicant (for all designated States except US):  
**RECKITT & COLMAN PRODUCTS LIMITED**  
[GB/GB]; 67 Alma Road, Windsor, Berkshire SL4 3HD  
(GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHAPLEO,**  
**Christopher, Bourne** [GB/GB]; Linden House, The  
Falconers, Redbourne, Gainsborough DN21 4AS (GB).

**MCCORMACK, Keith** [GB/GB]; Church House, Church  
Square, Leighton Buzzard, Bedfordshire LU7 7AE (GB).  
**VAREY, Nicolas, Calvert** [GB/GB]; "Caduceus", Main  
Street, Knedlington, Goole, North Humberside DN14 7EU  
(GB).


(74) Agent: **DICKSON, Elizabeth, Anne**; Reckitt Benckiser  
plc, Group Patents Dept., Dansom Lane, Hull HU8 7DS  
(GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: **PHARMACEUTICAL COMPOSITIONS**



(57) Abstract: An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmeferene such that the ratio by weight of buprenorphine to naltrexone or nalmeferene is in the range of from 12.5:1 to 22.5:1, whereby the analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmeferene.



**WO 01/35942 A2**



**Published:**

— Without international search report and to be republished upon receipt of that report.

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

PHARMACEUTICAL COMPOSITIONS

The present invention relates to analgesic compositions, containing buprenorphine and, in particular, to compositions which contain buprenorphine at a sub-clinical analgesic dose level in combination with naloxone, naltrexone or nalmeffene.

Buprenorphine (International Non-proprietary Name for N-cyclopropylmethyl-7 $\alpha$ -(1-(S)-hydroxy-1,2,2-trimethylpropyl]6,14-endoethano-6,7,8,14-tetrahydro-nororipavine) has been shown in clinical trials to be a potent opiate partial agonist analgesic lacking the psychotomimetic effects found with other opiate analgesics. Buprenorphine effectively relieves moderate to severe pain in doses of 0.1 mg or more administered either parenterally or sublingually. The optimum therapeutic range for single doses is 0.3 mg - 0.6 mg by injection and 0.2 mg-0.8 mg for sublingual tablets.

In animal tests and in man buprenorphine has been shown to have both agonist (morphine-like) and antagonist properties. However from direct dependence studies in animals and in man it has been concluded that buprenorphine does not produce significant physical dependence, as indicated by animal self administration studies and by the measurement of euphorigenic effects in human post addicts. However, buprenorphine suffers from side effects typical of opiate agonists such as nausea and vomiting, constipation and respiratory depression in some patients, although there is a ceiling to its effects on respiratory depression as a direct consequence of its partial agonist properties.

Naloxone (International Non-proprietary Name for 1-N-allyl-14-hydroxynorhydromorphinone) is a narcotic antagonist which has been incorporated into oral and sublingual preparations of various opioids in order to protect the preparations from parenteral abuse, whilst maintaining the analgesic effect of the opioid.

GB-A-2150832 describes analgesic compositions in sublingual or parenteral dosage form comprising an active

2-

dose of buprenorphine and an amount of naloxone sufficient to prove aversive to a narcotic addict by parenteral administration but insufficient to compromise the analgesic action of the buprenorphine. Preferably the parenteral dosage form contains naloxone and buprenorphine within the weight ratio of 1:3 to 1:1 and the sublingual form within the ratio 1:2 to 2:1.

Naltrexone (International Non-proprietary Name for 1-N-cyclopropylmethyl-14-hydroxynordihydro-morphinone) is a pure opiate antagonist which, when administered orally (50 mg/day) as a maintenance drug for opiate addicts, blocks the effects of self-administered opiates and this contributes to the extinction of drug craving.

Nalmefene (International Non-Proprietary Name for (5 $\alpha$ )-17-(cyclopropylmethyl)-4,5-epoxy-6-methylene-morphinan-3,14-diol) is a structural analogue of naltrexone with opiate antagonist activity.

GB-A-2167633 describes an analgesic composition in parenteral or sublingual unit dosage form comprising an active dose of buprenorphine and an amount of naltrexone sufficient to prove aversive to a narcotic addict by parenteral administration but insufficient to compromise the analgesic action of the buprenorphine wherein the dose of buprenorphine in the parenteral form is from about 0.3mg to about 0.6mg and in the sublingual form from about 0.1mg to about 0.4mg and the weights of buprenorphine to naltrexone for the parenteral form are within the ratio of 12:1 to 3:1 and for the sublingual form are within the ratio 4:1 to 1:1.

We have now surprisingly found that sub-clinical dosage levels of buprenorphine are potentiated and enhanced by low doses of naloxone or naltrexone or nalmefene. The interaction between the drugs is a synergistic interaction and more than the additive effects of the separate drug entities.

Accordingly, the present invention provides in its broadest aspect an analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of



3 -

buprenorphine which is less than the clinical dose required to achieve pain relief and

- (i) an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or
- (ii) an amount of naltrexone or nalmeferine such that the ratio by weight of buprenorphine to naltrexone or nalmeferine is in the range of from 12.5:1 to 22.5:1

whereby the analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmeferine.

In a first aspect the present invention provides an analgesic composition in parenteral or sublingual unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising from 15µg to 200µg of buprenorphine per unit dose and

- (i) an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or
- (ii) an amount of naltrexone or nalmeferine such that the ratio by weight of buprenorphine to naltrexone or nalmeferine is in the range of from 12µ5:1 to 22µ5:1.

It is to be understood that the terms buprenorphine, naloxone, naltrexone and nalmeferine as used herein are meant to cover not only the bases but their pharmaceutically acceptable salts. Particularly preferred salts are the hydrochlorides.

It is preferable to formulate the compositions in unit dosage forms i.e. physically discrete units containing the appropriate amounts of buprenorphine and naloxone, naltrexone or nalmeferine, together with pharmaceutically acceptable diluents and/or carriers.

Such unit dosage forms for parenteral administration are suitably in the form of ampoules and for delivery via the mucosa may, for example, be in the form of tablets for sublingual administration.

4 -

The term parenteral is intended to encompass administration of the compositions by any way other than through the alimentary tract.

5 The term mucosa is intended to encompass any mucous membrane and includes oral mucosa, rectal mucosa, vaginal mucosa and nasal mucosa.

Compositions intended for parenteral administration comprise an isotonic solution of buprenorphine and naloxone, naltrexone or nalmefene in sterile water. 10 Conveniently the solution is made isotonic by use of dextrose and sterilised by autoclaving or by filtration through a membrane filter. The compositions may be administered intramuscularly, intradermally, intraperitoneally, intravenously, intraarterially, 15 subcutaneously or by the epidural route. The compositions may also be administered transdermally.

Compositions in the form of sublingual tablets contain soluble excipients such as lactose, mannitol, dextrose, sucrose or mixtures thereof. They will also 20 contain granulating and disintegrating agents such as starch, binding agents such as povidone or hydroxypropyl-methyl cellulose and lubricating agents such as magnesium stearate.

25 The compositions for parenteral administration, or for delivery via the mucosa, such as by sublingual administration, as detailed above, may be prepared by manufacturing techniques which are well known to those skilled in the art.

30 The compositions of the present invention in unit dosage form preferably contain the naloxone, naltrexone or nalmefene in an amount such that the ratio by weight of buprenorphine to naloxone, naltrexone or nalmefene is in the range of from 15:1 to 20:1.

35 The compositions of the present invention contain buprenorphine in an amount which is below that required in a unit dose to obtain pain relief. In the human being, dosages of about 40µg of buprenorphine per kilogram of body weight are required to obtain satisfactory pain relief in the absence of potentiation.

5 -

Thus for typical body weights of 50 to 80 kg, the dosage would be from 2000µg to 3200µg, i.e. from 2mg to 3.2mg of buprenorphine per day. This would conveniently be administered as 4 unit doses. The amounts of

5 buprenorphine which are effective in the present invention are below the amounts which are effective in the absence of the potentiating effects of naloxone, naltrexone or nalmeffene.

In a second aspect the present invention provides a method for the treatment of pain in a human or animal

10 subject, which method comprises the administration to the human or animal by the parenteral or via the mucosa route of from 1.25µg to 10µg per kilogram of body weight of buprenorphine per day and

15 (i) an amount of naloxone such that the ratio by weight of buprenorphine to naloxone administered is in the range of from 12.5:1 to 27.5:1, or

(ii) an amount of naltrexone or nalmeffene such that

20 the ratio by weight of buprenorphine to naltrexone or nalmeffene administered is in the range of from 12.5:1 to 22.5:1.

In a third aspect the present invention provides the use

25 of naloxone, naltrexone or nalmeffene in the manufacture of a medicament for the treatment of pain comprising a sub-clinical amount of buprenorphine, wherein the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1 or the ratio by weight of

30 buprenorphine to naltrexone or nalmeffene is in the range of from 12.5:1 to 22.5:1.

The ratios for the potentiation of the sub-clinical dosages of buprenorphine by low doses of the opiate antagonists were determined by the University Department

35 of Anaesthesia, Addenbrookes Hospital, Cambridge according to the paw withdrawal method of Hargreaves, K.M., Dubner, R., Brown, F., Flores, C. and Joris, J.: A New and Sensitive Method for Measuring Thermal Nociception in Cutaneous Hyperalgesia. Pain 32: 77-88,

6-

1988. This method enables the researcher to discern a peripherally mediated response to thermal stimulation caused by drugs in the unrestrained rat.

5 The results were obtained using a BASILE Plantar Test Device (Ugo Basile, Comerio-Italy). It basically consists of a movable I.R. (infrared) Generator placed below a glass pane upon which the operator places the rat. A perspex enclosure defines the space within which the animal is unrestrained. It is divided into three  
10 compartments, which helps the operator to carry out rapid "screening" work: up to three rats can be tested with no appreciable delay in between.

The operator positions the I.R. Generator directly beneath the hind paw of the rat and activates both the  
15 I.R. Source and a reaction time counter. When the rat feels pain and withdraws its paw, the I.R. Generator is automatically switched off and the timer stops, determining the withdrawal latency.

The effects of buprenorphine at various dosages, naloxone at various dosages, naltrexone at various  
20 dosages and buprenorphine in combination with naloxone or naltrexone at various dosages were determined by testing adult rats in which peripheral mononeuropathy was produced by placing three loosely constrictive ligatures  
25 around the common sciatic nerve. The testing was carried out on the eighth day following the operative procedure.

In order to determine a baseline for comparison purposes, rats were subjected to the Hargreaves paw withdrawal test before the subcutaneous injection of the  
30 various drugs or drug combinations being tested. The rats were then injected subcutaneously with the particular drug or drug combination being tested and the percentage change in time for the rat to withdraw its paw from the thermal stimulation, in comparison with the  
35 baseline, was recorded as a percentage in paw withdrawal latency.

The invention is further described with reference to the following Examples.

7-

## METHODS

### Surgery

5 Lister Hooded rats (180-200g) were anaesthetised with halothane and the left sciatic nerve was loosely ligated with 3 chromic cat gut sutures to induce a neuropathy.

Rats were left to recover for one week after the procedure before commencing behavioural testing.

### Drug Preparation

10 The drugs (buprenorphine, naloxone and naltrexone) were prepared freshly in water at a concentration of 1 mg/ml. The stocks were then diluted in saline to obtain the different concentrations used in the study.

Drugs were injected sub-cutaneously in the fold of the neck.

### Testing

20 After 8 days, thermal nociceptive threshold, as determined by hindpaw withdrawal latency, was measured using a plantar test Ugo Basile, Comerio, Italy). Prior to testing, the rat was placed in the perspex box and allowed 5 minutes to habituate. The heat source was  
25 positioned under the plantar surface of one hind paw at random and activated. This initiated a timing circuit which measured the time interval between the application of the light beam and the withdrawal of the hind paw. This value was assigned as the withdrawal latency.

30 Paw withdrawal latency was determined before injection and at different times after injection. Three measurements were taken per paw.

### EXAMPLE 1

35 The effects of buprenorphine and buprenorphine/naloxone at weight ratios of 20:1 and 15:1 were determined at various doses of buprenorphine expressed as

8-

µg/kg of body weight of the drug administered subcutaneously to rats (n=3).

The results of these tests are given in Figure 1. The potentiation of sub-clinical doses of buprenorphine by low dose naloxone can be clearly seen from the graph of Figure 1. Both of the buprenorphine/naloxone combinations showed marked increases in pain withdrawal latencies at both weight ratios where the buprenorphine dose was 1.25µg and 2.5µg, compared to buprenorphine alone which had no significant effect at these dosage levels.

#### EXAMPLE 2

Buprenorphine was administered to rats (n=6) at a dosage level of 2.5µg/kg of body weight of the rats. Buprenorphine was co-administered subcutaneously with either naloxone or naltrexone at various weight ratios ranging from 5:1 to 30:1. In order to provide appropriate baseline points naloxone and naltrexone alone were also administered subcutaneously to rats at the same dosage levels as those used in the combined treatments.

The results are given in Figure 2 from which the potentiation of the sub-clinical doses of buprenorphine by naloxone or naltrexone can be clearly seen.

#### EXAMPLE 3

To investigate the duration of action of several ratios (10:1, 15:1 and 20:1 buprenorphine:naloxone, with a fixed dose of buprenorphine) the effect on PWL was followed over a 26 hour period following subcutaneous injection. The results are given in Figure 3 from which it can be seen that the effect was already maximal after 40 minutes and then decreased sharply over 6 hours. However at 26 hours a residual effect was still visible, although this was not statistically significant. The maximal effect of each ratio (40min) was compatible with the results shown in Figure 2. The effect observed with

the 10:1 ratio combination was not statistically significant.

#### EXAMPLE 4

5

A parenteral formulation having the following composition:

		mg/ml.
	Buprenorphine HCl	0.1
10	Naloxone HCl	0.0067
	Anhydrous dextrose	50.0
	Hydrochloric acid to pH	4.0
	Water for injection to	1.0 ml

15 was prepared by dissolving dextrose, buprenorphine hydrochloride and naloxone hydrochloride in that order with stirring, in about 95% batch volume of Water for Injection. The acidity of the solution was adjusted to pH 4.0 by the addition of 0.1M hydrochloric acid, and the  
20 solution was made up to volume with Water for Injection. The solution was filtered through a 0.22  $\mu$ m membrane filter and transferred to sterilised 1 ml or 2 ml glass ampoules containing 1 ml or 2 ml of the solution. The ampoules were sealed and the product sterilised by  
25 autoclaving.

#### EXAMPLE 5

The formulation of Example 4 was varied by using  
30 0.005 mg/ml of naloxone hydrochloride instead of 0.0067 mg/ml.

#### EXAMPLE 6

35 The formulation of Example 4 was modified with 0.0067 mg/ml of naltrexone hydrochloride substituted for the naloxone hydrochloride of Example 1.

10 -

EXAMPLE 7

The formulation of Example 4 was modified with  
0.005 mg/ml of naltrexone hydrochloride substituted for  
5 the naloxone hydrochloride of Example 1.

EXAMPLE 8

The formulation of Example 4 was modified with  
10 0.0067 mg/ml of nalmefene hydrochloride substituted for  
the naloxone hydrochloride of Example 4.

EXAMPLE 9

15 The formulation of Example 4 was modified with  
0.005 mg/ml of nalmefene hydrochloride substituted for  
the naloxone hydrochloride of Example 4.

EXAMPLE 10

20

A sublingual tablet having the following  
composition:

	mg/tablet
25 Buprenorphine HCl	0.1
Naloxone HCl	0.0067
Lactose	31.2433
Mannitol	18.0
Maize starch	9.0
Povidone	1.2
30 Magnesium stearate	<u>0.45</u>
	60.0

was prepared by screening all the materials with the  
exception of the magnesium stearate through a 750  $\mu$ m  
sieve and blending them together. The mixed powders were  
35 then subjected to an aqueous granulation procedure and  
dried at 50°C. The resulting granules were forced  
through a 750  $\mu$ m sieve and blended with magnesium  
stearate (pre-sieved through a 500  $\mu$ m sieve). The tablet



11 -

granules were compressed to yield tablets of 5.56 mm diameter and weight 60 mg.

EXAMPLE 11

5

The formulation of Example 10 was varied by using 0.005 mg/tablet of naloxone hydrochloride and adjusting the weight of lactose.

10

EXAMPLE 12

The formulation of Example 10 was modified with 0.0067 mg/tablet of naltrexone hydrochloride substituted for the naloxone hydrochloride of Example 10.

15

EXAMPLE 13

The formulation of Example 10 was modified with 0.005 mg/tablet of naltrexone hydrochloride substituted for the naloxone hydrochloride of Example 10.

20

EXAMPLE 14

The formulation of Example 10 was modified with 0.0067 mg/tablet of nalmefene hydrochloride substituted for the naloxone hydrochloride of Example 10.

25

EXAMPLE 15

The formulation of Example 10 was modified with 0.005 mg/tablet of nalmefene hydrochloride substituted for the naloxone hydrochloride of Example 10.

30

35

12 -

EXAMPLE 16

A suppository having the following composition:

	mg/suppository
5      Buprenorphine HCL	0.1
Naloxone HCL	0.0067
Gelatin	200
Glycerin	700
Deionised water	89.9

10

was prepared by mixing the ingredients together and melting them at between 60° and 70°C. The melted mass is poured into a disposable mould of plastic material in which the suppositories are cast and remain enclosed until removed by the patient.

15

EXAMPLE 17

The formulation of Example 16 was varied by using 0.005mg/suppository of naloxone hydrochloride.

20

EXAMPLE 18

The formulation of Example 16 was modified with 0.0067 mg/suppository of naltrexone hydrochloride substituted for the naloxone hydrochloride of Example 16.

25

EXAMPLE 19

The formulation of Example 16 was modified with 0.005 mg/suppository of naltrexone hydrochloride substituted for the naloxone hydrochloride of Example 16.

30

EXAMPLE 20

The formulation of Example 16 was modified with 0.0067 mg/suppository of nalmeffene hychloride substituted for the naloxone hydrochloride of Example 16.

35

13 -

EXAMPLE 21

The formulation of Example 16 was modified with  
0.005mg/suppository of nalmeferne hydrochloride  
5 substituted for the naloxone hydrochloride of Example 16.

14-

## CLAIMS:

1. An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and

- (i) an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or
- (ii) an amount of naltrexone or nalmeferine such that the ratio by weight of buprenorphine to naltrexone or nalmeferine is in the range of from 12.5:1 to 22.5:1
- whereby the analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmeferine.

2. An analgesic composition in parenteral or sublingual unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising from 15µg to 200µg of buprenorphine per unit dose and
- (i) an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or
- (ii) an amount of naltrexone or nalmeferine such that the ratio by weight of buprenorphine to naltrexone or nalmeferine is in the range of from 12.5:1 to 22.5:1.

15 -

3. A composition as claimed in claim 1 or claim 2 wherein the unit dosage form contains an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 15:1 to 20:1.

5

4. A composition as claimed in claim 1 or claim 2 wherein the dosage form contains an amount of naltrexone or nalmeferine such that the ratio by weight of buprenorphine to naltrexone or nalmeferine is in the range of from 15:1 to 20:1.

10

5. A method for the treatment of pain in a human or animal subject, which method comprises the administration to the human or animal by the parenteral or via the mucosa route of from 1.25µg to 10µg per kilogram of body weight of buprenorphine per day and

15

(i) an amount of naloxone such that the ratio by weight of buprenorphine to naloxone administered is in the range of from 12.5:1 to 27.5:1, or

20

(ii) an amount of naltrexone or nalmeferine such that the ratio by weight of buprenorphine to naltrexone or nalmeferine administered is in the range of from 12.5:1 to 22.5:1.

25

6. A method as claimed in claim 5 wherein the amount of buprenorphine administered to the human or animal is from 1.25µg to 5µg per kilogram of body weight.

30

7. A method as claimed in claim 5 or claim 6 wherein the ratio by weight of buprenorphine to naloxone,

16-

naltrexone or nalmeferine administered to the human or animal is in the range of from 15:1 to 20:1.

8. Use of naloxone, naltrexone or nalmeferine in the  
5 manufacture of a medicament for the treatment of pain  
comprising a sub-clinical amount of buprenorphine,  
wherein the ratio by weight of buprenorphine to naloxone  
is in the range of from 12.5:1 to 27.5:1 or the ratio by  
weight of buprenorphine to naltrexone or nalmeferine is in  
10 the range of from 12.5:1 to 22.5:1.

9. Use as claimed in claim 8 wherein the ratio by  
weight of buprenorphine to naloxone, naltrexone or  
nalmeferine is in the range of from 15:1 to 20:1.

15

10. An analgesic composition according to the  
invention, substantially as hereinbefore described or  
exemplified.

20 11. A method for the treatment of pain according to  
the invention, substantially as hereinbefore described or  
exemplified.

12. Use as claimed in either one of claims 8 or 9,  
25 substantially as hereinbefore described or exemplified.

Fig.1.




Fig.2.







Fig.3.



**THIS PAGE BLANK (USPTO)**